Seeking Alpha

Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals...

Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals in a Phase 3 study, and the biotech will now seek FDA and EU regulatory approval for the drug in 2013. Apremilast also achieved its primary goal in a separate study of patients with Behcet's disease, a rare inflammatory condition. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs